Summarized by Masters of Longevity from Longevity Technology.
Kailera’s update previews a pharmaceutical trial report on a new once-weekly obesity therapy’s global Phase 3 program and development plans.
Key Takeaways
- Kailera completed global Phase 3 enrollment for ribupatide, a once-weekly GLP-1/GIP dual agonist, with topline results expected in mid-2028.
- Each of the three double-blind, placebo-controlled 76-week trials includes dose escalation to a maintenance dose and compares ribupatide to placebo and, in one trial, open-label semaglutide 2.4 mg.
- Kailera also plans oral and multi-agonist programs, including a once-daily oral ribupatide entering Phase 3 in China and additional global trials planned in 2027.
